estriol has been researched along with Dyspareunia in 13 studies
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone
chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.
Dyspareunia: Recurrent genital pain occurring during, before, or after SEXUAL INTERCOURSE in either the male or the female.
| Excerpt | Relevance | Reference |
|---|---|---|
| "005% estriol gel to the vulvar vestibule in the management of postmenopausal dyspareunia." | 9.22 | Coital pain in the elderly: could a low dose estriol gel thrill the vulvar vestibule? ( Di Francesco, S; Felice, R; Graziottin, A; Murina, F, 2016) |
| "Our results showed that combination therapy with estriol plus pelvic floor rehabilitation was effective and should be considered as a first-line treatment for symptoms of urogenital aging in postmenopausal women." | 9.16 | Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. ( Borghero, G; Capobianco, G; Cherchi, PL; Dessole, F; Dessole, S; Donolo, E, 2012) |
| "The significant decline in gonadotropin levels, indicating systemic effects, has to be kept in mind when offering vaginal estriol to breast cancer patients receiving an aromatase inhibitor." | 9.15 | Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. ( Fink-Retter, A; Geisendorfer, T; Glatz, C; Königsberg, R; Kubista, E; Pfeiler, G; Seifert, M; Singer, CF, 2011) |
| "005% oestriol vaginal gel on dyspareunia in postmenopausal women within the first 2 weeks of treatment." | 8.12 | Effect of oestriol gel on dyspareunia in postmenopausal women in 2 weeks of treatment: a pilot study. ( Cuerva, MJ; González, SP; Lazaro-Carrasco De La Fuente, J; Lopez, FJ; Nieto, C, 2022) |
| "Vulvodynia and pudendal neuralgia comprise significant contributors to vulvar-related pain and its impact on daily life." | 5.62 | Topical treatment of vulvodynia, dyspareunia and pudendal neuralgia: A single clinic audit of amitriptyline and oestriol in organogel. ( Chan, K; Howard, EA; Ruoss, CM; Stevenson, PG; Vancaillie, T, 2021) |
| "005% estriol gel to the vulvar vestibule in the management of postmenopausal dyspareunia." | 5.22 | Coital pain in the elderly: could a low dose estriol gel thrill the vulvar vestibule? ( Di Francesco, S; Felice, R; Graziottin, A; Murina, F, 2016) |
| "Our study showed that vaginal supplementation with estriol 50 μg/g gel or with hyaluronic acid could reduce the de novo dyspareunia related to COC." | 5.20 | A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive. ( Bogani, G; Braghiroli, A; Cromi, A; Di Dedda, MC; Ghezzi, F; Serati, M; Uccella, S, 2015) |
| "Our results showed that combination therapy with estriol plus pelvic floor rehabilitation was effective and should be considered as a first-line treatment for symptoms of urogenital aging in postmenopausal women." | 5.16 | Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. ( Borghero, G; Capobianco, G; Cherchi, PL; Dessole, F; Dessole, S; Donolo, E, 2012) |
| "The significant decline in gonadotropin levels, indicating systemic effects, has to be kept in mind when offering vaginal estriol to breast cancer patients receiving an aromatase inhibitor." | 5.15 | Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. ( Fink-Retter, A; Geisendorfer, T; Glatz, C; Königsberg, R; Kubista, E; Pfeiler, G; Seifert, M; Singer, CF, 2011) |
| " Postmenopausal genital and urinary problems with recurrent infections, incontinence, and dyspareunia can effectively be treated by vaginal application of estriol, which seems to be safe for women treated for breast cancer." | 4.91 | Hormones, herbal preparations and nutriceuticals for a better life after the menopause: part I. ( Comhaire, FH; Depypere, HT, 2015) |
| "005% oestriol vaginal gel on dyspareunia in postmenopausal women within the first 2 weeks of treatment." | 4.12 | Effect of oestriol gel on dyspareunia in postmenopausal women in 2 weeks of treatment: a pilot study. ( Cuerva, MJ; González, SP; Lazaro-Carrasco De La Fuente, J; Lopez, FJ; Nieto, C, 2022) |
| "Vulvodynia and pudendal neuralgia comprise significant contributors to vulvar-related pain and its impact on daily life." | 1.62 | Topical treatment of vulvodynia, dyspareunia and pudendal neuralgia: A single clinic audit of amitriptyline and oestriol in organogel. ( Chan, K; Howard, EA; Ruoss, CM; Stevenson, PG; Vancaillie, T, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia de Arriba, S | 1 |
| Grüntkemeier, L | 1 |
| Häuser, M | 1 |
| May, TW | 1 |
| Masur, C | 1 |
| Stute, P | 2 |
| Cuerva, MJ | 1 |
| González, SP | 1 |
| Lazaro-Carrasco De La Fuente, J | 1 |
| Lopez, FJ | 1 |
| Nieto, C | 1 |
| Ruoss, CM | 1 |
| Howard, EA | 1 |
| Chan, K | 1 |
| Stevenson, PG | 1 |
| Vancaillie, T | 1 |
| Gray, S | 1 |
| Comhaire, FH | 1 |
| Depypere, HT | 1 |
| Serati, M | 1 |
| Bogani, G | 1 |
| Di Dedda, MC | 1 |
| Braghiroli, A | 1 |
| Uccella, S | 1 |
| Cromi, A | 1 |
| Ghezzi, F | 1 |
| Murina, F | 1 |
| Graziottin, A | 1 |
| Felice, R | 1 |
| Di Francesco, S | 1 |
| Pfeiler, G | 1 |
| Glatz, C | 1 |
| Königsberg, R | 1 |
| Geisendorfer, T | 1 |
| Fink-Retter, A | 1 |
| Kubista, E | 1 |
| Singer, CF | 1 |
| Seifert, M | 1 |
| Capobianco, G | 1 |
| Donolo, E | 1 |
| Borghero, G | 1 |
| Dessole, F | 1 |
| Cherchi, PL | 1 |
| Dessole, S | 1 |
| Milchev, N | 1 |
| Grozdanov, G | 1 |
| Krumov, G | 1 |
| Abraham, S | 1 |
| Grio, R | 1 |
| Mazza, O | 1 |
| Cellura, A | 1 |
| Zaccheo, F | 1 |
| Giobbe, C | 1 |
| Marchino, GL | 1 |
| Malara, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of C02 Microfractionated Laser in Conjunction With Topical Regenerative Therapy in the Management of Vulvo-vaginal Atrophy in Patients With a History of Breast Cancer. Randomized Experimental and Comparative Study.[NCT05585476] | 98 participants (Anticipated) | Interventional | 2022-12-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for estriol and Dyspareunia
| Article | Year |
|---|---|
Hormones, herbal preparations and nutriceuticals for a better life after the menopause: part I.
Topics: Breast Neoplasms; Cardiovascular Diseases; Dietary Supplements; Dyspareunia; Estradiol; Estriol; Est | 2015 |
5 trials available for estriol and Dyspareunia
| Article | Year |
|---|---|
Vaginal hormone-free moisturising cream is not inferior to an estriol cream for treating symptoms of vulvovaginal atrophy: Prospective, randomised study.
Topics: Administration, Intravaginal; Atrophy; Dyspareunia; Estriol; Female; Humans; Male; Postmenopause; Pr | 2022 |
A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive.
Topics: Adult; Atrophy; Contraceptives, Oral, Hormonal; Drug Administration Schedule; Dyspareunia; Estriol; | 2015 |
Coital pain in the elderly: could a low dose estriol gel thrill the vulvar vestibule?
Topics: Aged; Aging; Atrophy; Drug Administration Schedule; Dyspareunia; Estriol; Estrogens; Female; Gels; H | 2016 |
Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients.
Topics: Administration, Intravaginal; Aromatase Inhibitors; Breast Neoplasms; Chromatography, Gas; Drug Moni | 2011 |
Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women.
Topics: Administration, Intravaginal; Aging; Analysis of Variance; Atrophy; Dyspareunia; Electric Stimulatio | 2012 |
7 other studies available for estriol and Dyspareunia
| Article | Year |
|---|---|
Effect of oestriol gel on dyspareunia in postmenopausal women in 2 weeks of treatment: a pilot study.
Topics: Dyspareunia; Estriol; Female; Humans; Pilot Projects; Postmenopause; Prospective Studies; Vagina; Va | 2022 |
Topical treatment of vulvodynia, dyspareunia and pudendal neuralgia: A single clinic audit of amitriptyline and oestriol in organogel.
Topics: Aged; Amitriptyline; Australia; Clinical Audit; Dyspareunia; Estriol; Female; Humans; Middle Aged; P | 2021 |
Practice observed.
Topics: Anemia, Pernicious; Contraceptives, Oral, Synthetic; Crohn Disease; Cystitis, Interstitial; Desogest | 2018 |
Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief?
Topics: Administration, Intravaginal; Adult; Aged; Dyspareunia; Estriol; Female; Humans; Hyaluronic Acid; Mi | 2013 |
[Practical observations on the use of the Ortho-Gynest vaginal globules from the firm of Cillag--Switzerland].
Topics: Administration, Intravaginal; Aged; Drug Evaluation; Dyspareunia; Estriol; Female; Humans; Middle Ag | 1993 |
Recovery after childbirth.
Topics: Breast Feeding; Dyspareunia; Estriol; Female; Humans; Pregnancy; Puerperal Disorders | 1990 |
[Topical therapy of postmenopausal dyspareunia].
Topics: Administration, Intravaginal; Dyspareunia; Estriol; Female; Humans; Menopause; Middle Aged; Vaginal | 1988 |